Sciwind begins clinical trial of XW014 for Obesity and T2DMSciwind Biosciences has initiated of dosing in a Phase 1 clinical trial evaluating XW014, a novel oral small molecule glucagon-like...
LSG and RYGB-induced upregulation of apoA-IV is beneficial for insulin secretion and energy expenditure22 hours ago
Tirzepatide reduced sleep apnoea severity by up to nearly two-thirds in adults living with OSA and obesity22 hours ago